Trigeminal neuralgia, also known as Fotrergin’s disease, is a common neurological disorder that is characterized by recurrent severe pain in the area of the trigeminal nerve distribution in the face. The facial pain is most common in the area of distribution of trigeminal nerve branches 2 and 3 (roughly located from the eyelid and lateral side of the nasal bridge down to the mandible). Trigeminal neuralgia is divided into primary and secondary. The pathogenesis of primary trigeminal neuralgia is mostly thought to be due to local vascular compression of the trigeminal nerve. 85% of the cases are due to arterial compression, mainly the superior cerebellar artery and the anterior inferior cerebellar artery, etc. Secondary trigeminal neuralgia is mainly caused by the compression of nerves by tumors in the pontocerebellar angle, pontocerebellum and lateral cerebellum, such as cholesteatoma, auditory neuroma, meningioma, etc. The main manifestations of primary trigeminal neuralgia: Pain nature: Sudden pain, which is characterized by a sudden and severe lightning-like brief throbbing pain at a certain point of the face, mouth and jaw, like a knife cut, fire, needle prick or electric shock tearing-like pain, mostly occurs when talking, eating or washing the face, each time experiencing a few seconds or up to tens of seconds to 1-2 minutes, the pain immediately spreads to one or several branches of the trigeminal nerve. Pain site: trigeminal nerve distribution area: the pain is mostly on one side, with the 2nd or 3rd branch or the area innervated by the 2nd and 3rd branches being the most common. More than 50% of patients have a particularly sensitive area in a certain area of the face, and pain can be triggered by slight touch or stimulation, such as talking, singing, washing, shaving, brushing, wind blowing, etc. Primary trigeminal neuralgia treatment: medication, peripheral branch closure, radiofrequency of the semilunar ganglion, microvascular decompression, etc. Drug treatment firstly carbamazepine, usage, starting dose 0.1g, orally, 2-3 times/day; later gradually increase 0.1g, maximum daily dose not more than 1.6g. Other drugs are sodium valproate, hepatichylline, etc. Microvascular decompression: Microvascular decompression is the use of microsurgical treatment to remove the vessels (arteries or veins) associated with the trigeminal nerve and isolate the nerve with decompression materials such as tefflon, gelatin sponge, etc. This is an ideal surgical method to remove the cause of the disease, and the pain relief rate of this surgical method is over 90%. Indications for microvascular decompression 1, long-term drug treatment, pain relief effect is weakened or ineffective, allergic to drugs can not be adhered to, willing to surgery; 2, the use of closed agent radiofrequency treatment relapse; 3, no serious disease of the important organs of the body, age under 70 years old; 4, trigeminal neuralgia with facial muscle twitching.